Phibro acquires vaccines manufacturer

The acquisition strengthens Phibro’s position in fish vaccine innovation and expands its portfolio of aquaculture products.

KoVax’s research and development team has joined Phibro’s biological R&D team, and will focus on developing a pipeline of innovative vaccines for the aquaculture market.

Phibro’s first commercial aquaculture vaccine is KoVax’s “KV3” vaccine, which helps prevent Koi Herpes Virus, a highly contagious disease that can cause significant mortality in common carp farms.